复方血栓通滴丸对视网膜静脉阻塞患者血清VEGF及眼血流动力学指标的影响

doi:10.3969/j.issn.1671-7171.2025.01.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1173 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨复方血栓通滴丸对视网膜静脉阻塞患者血清血管内皮细胞生长因子(VEGF)及眼血流动力学指标的影响。【方法】选取2019年1月至2022年3月陕西省城固县中医医院收治的80例视网膜静脉阻塞患者,采用随机数字表法分为对照组(采用常规药物治疗)和观察组(在对照组的基础上加用复方血栓通滴丸),每组40例。比较两组治疗后疗效及治疗前后中医症状评分、VEGF水平、内皮素-1(ET-1)水平、一氧化氮(NO)水平、收缩期峰值血流速度(PSV)、舒张末期血流速度(EDV)、阻力指数(RI)。【结果】观察组有效率为95.00%,显著高于对照组的80.00%(P<0.05)。治疗后,观察组视力骤降、胸胁胀闷、眼胀评分均低于治疗前及对照组治疗后(P<0.05)。治疗后,观察组VEGF、ET-1水平均明显低于治疗前及对照组治疗后,NO水平高于治疗前及对照组治疗后(P<0.05)。治疗后,观察组RI明显低于治疗前及对照组治疗后,PSV、EDV均明显高于治疗前及对照组治疗后(P<0.05)。【结论】复方血栓通滴丸用于视网膜静脉阻塞患者治疗中,疗效显著,能明显改善患者中医症状评分和眼血流动力学指标,降低VEGF、ET-1水平。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	向彦锋
	刘建利

关键词 ：视网膜静脉闭塞, 血管内皮生长因子A, 血流动力学

Abstract：【Objective】To investigate the effects of fufang xueshuantong dripping pills on serum vascular endothelial growth factor (VEGF) and ocular hemodynamics in patients with retinal vein obstruction. 【Methods】 A total of 80 patients with retinal vein obstruction admitted to Chenggu County Hospital of Traditional Chinese Medicine in Shaanxi Province from January 2019 to March 2022 were selected and divided into the control group (receiving conventional drug treatment) and the observation group (adding fufang xueshuantong dripping pill to the control group) by random number table method, with 40 cases in each group. After treatment, Chinese medicine symptom score, VEGF level, endothelin-1 (ET-1) level, nitric oxide (NO) level, peak systolic blood velocity (PSV), end-diastolic blood velocity (EDV) and resistance index (RI) were compared between the two groups.【Results】The effective rate of the observation group was 95.00%, which was significantly higher than that of the control group 80.00% (P<0.05). After treatment, the visual acuity drop, chest and hypochthonic distension and eye distension scores in the observation group were lower than those before and after treatment in the control group (P<0.05). After treatment, the levels of VEGF and ET-1 in the observation group were significantly lower than before treatment and after treatment in the control group, and NO was higher than before treatment and after treatment in the control group (P<0.05). After treatment, RI in the observation group was significantly lower than before treatment and after treatment in the control group, PSV and EDV were significantly higher than before treatment and after treatment in the control group (P<0.05).【Conclusion】The Xueshuantong dripping pill has a significant effect in the treatment of patients with retinal vein obstruction, which can significantly improve the TCM symptom score and eye hemodynamic index, and reduce the levels of VEGF and ET-1.

Key words： Retinal Vein Occlusion Vascular Endothelial Growth Factor A Hemodynamics

收稿日期: 2023-11-16

中图分类号:

R774.1

通讯作者: *E-mail:zhhb1011@sina.com

引用本文:

向彦锋, 刘建利. 复方血栓通滴丸对视网膜静脉阻塞患者血清VEGF及眼血流动力学指标的影响[J]. 医学临床研究, 2025, 42(1): 88-91.
XIANG Yanfeng, LIU Jianli. Effects of Fufang Xueshuantong Dripping Pills on Serum VEGF and Ocular Hemodynamic Indexes in Patients with Retinal Vein Obstruction. JOURNAL OF CLINICAL RESEARCH, 2025, 42(1): 88-91.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.01.025 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I1/88

[1] YIN X, LI J Q, ZHANG B Y,et al. Association of glaucoma with risk of retinal vein occlusion: a meta-analysis[J].Acta Ophthalmol,2019,97(7):652-659.
[2] CHEN L L, YUAN M Z, SUN L,et al. Choroidal thickening in retinal vein occlusion patients with serous retinal detachment[J].Graefes Arch Clin Exp Ophthalmol,2021,259(4):883-889.
[3] CASSELHOLM DE SALLES M, LINDBERG C, EPSTEIN D. Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-vegf era[J].Acta Ophthalmol,2021,99(1):7-12.
[4] 王丹. 复方血栓通滴丸结合卵磷脂络合碘治疗视网膜静脉阻塞临床疗效及安全性研究[J].广州医科大学学报,2022,50(4):75-79.
[5] 刘佳琦,李凤鸣. 实用眼科学[M].北京:人民出版社:2010:31-34.
[6] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994:56-57.
[7] 杨杰,彭南祥,陈季生. 玻璃体腔注射不同药物联合激光治疗视网膜静脉阻塞合并黄斑水肿的疗效比较[J].国际眼科杂志,2017,17(10):1912-1914.
[8] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国中医药出版社,2002:253-258.
[9] 孙岩,马健萍,徐茂生,等. 复方血栓通滴丸治疗视网膜静脉阻塞的临床安全性与有效性观察[J].辽宁中医杂志,2020,47(3):133-136.
[10] 相自越,罗向霞,王虹强,等. 血栓通离子导入联合康柏西普玻璃体腔注射治疗视网膜静脉阻塞合并黄斑水肿[J].国际眼科杂志,2021,21(12):2150-2155.
[11] 孙运祥,左韬,张祝强,等. 化瘀明目复方联合注射用血栓通离子导入治疗气阴两虚型糖尿病视网膜病变疗效观察[J].天津中医药大学学报,2021,40(6):744-747.
[12] 王珏,杜玮,李燕. 羟苯磺酸钙联合复方血栓通胶囊治疗老年糖尿病视网膜病变的疗效及对血液流变学的影响[J].中国老年学杂志,2020,40(8):1603-1606.
[13] 徐思琪,龚雨婷,王林农,等. 血栓通胶囊对视网膜中央静脉阻塞患者视网膜微循环、黄斑水肿及内皮素-1表达的影响[J].临床与病理杂志,2022,42(8):1968-1975.
[14] 相自越,王虹强,王莎,等. 血栓通注射液离子导入联合抗VEGF治疗视网膜静脉阻塞性黄斑水肿的临床疗效[J].川北医学院学报,2022,37(4):469-472.
[15] 肖姗姗,唐冰. 麝香通心滴丸联合血栓抽吸改善STEMI患者PCI术后心肌血流灌注的临床研究[J].海南医学院学报,2017,23(4):460-463.